ResearcherPurdue University West LafayetteActive in the last 2 years

Claire M. Pfeffer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0045-2333; OpenAlex author ID A5088669266. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. Co-author DOI 10.1158/1535-7163.mct-25-0970 ↗
PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma First author DOI 10.1101/2025.07.14.664742 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Garima Baral · 2 shared papers, 2025–2026 · strength 0.44
- Paper PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma DOI 10.1101/2025.07.14.664742 ↗
- Paper Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. DOI 10.1158/1535-7163.mct-25-0970 ↗
Brittany L. Allen-Petersen · 2 shared papers, 2025–2026 · strength 0.44
- Paper PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma DOI 10.1101/2025.07.14.664742 ↗
- Paper Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. DOI 10.1158/1535-7163.mct-25-0970 ↗
Jennifer P. Morton · 1 shared paper, 2026 · strength 0.22
- Paper Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. DOI 10.1158/1535-7163.mct-25-0970 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.